PRESS
RELEASE
BioLife Solutions Presents Data on CryoStor™at International Society for Cellular Therapy Annual Meeting
Independent Study Indicates 20-50% Improvement in Post-Preservation Functional Recovery
of Peripheral Blood Stem Cells for Cancer Therapy
BOTHELL,WA – June 25, 2007 – BioLife Solutions Inc. (OTCBB: BLFS), a leading developer and marketer of
proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs,
today presented data from an independent study of its CryoStor family of cryopreservation media at the
annual meeting of the International Society for Cellular Therapy in Sydney, Australia.
The presentation by BioLife scientists summarized the results of a recent study conducted by researchers
at the Fred Hutchinson Cancer Research Center (FHCRC) and the University of Washington. BioLife’s
CryoStor preservation media was compared with a DMSO/HSA media formulation, currently considered
the “gold standard” for cryopreservation of peripheral blood stem cells. Peripheral blood stem cells are
the most common source of stem cells for transplantation to treat various blood disorders such as
leukemia.
Highlighted metrics evaluated in the study included Colony Forming Units (CFU), a key indicator of the
functional ability of cells to divide and replicate following cryopreservation, and total CD34+ cell recovery,
a key marker of a subpopulation of undifferentiated progenitor cells that are of critical interest to
researchers focused on hematopoietic cell therapies. The results of the study showed that BioLife’s
CryoStor technology platform produced a 20-50% relative improvement across these key parameters in
comparison to the 10% DMSO standard preservation media utilized at FHCRC.
Shelly Heimfeld, director of the cellular therapy laboratory at the Fred Hutchinson Cancer Research
Center, commented: “We were impressed by how much better the CryoStor patented media
formulations improved the post-preservation recovery of CD34+ and colony-forming cells. We will
continue our evaluations and validation of BioLife’s products with the hope to incorporate CryoStor into
our clinical applications.”
BioLife Chief Executive Mike Rice remarked: “We’re very pleased that world-class institutions like the
Fred Hutchinson Cancer Research Center and the University of Washington have confirmed the value of
BioLife’s intellectual property and CryoStor products which provide unique benefits to clinicians in their
fight against cancer and other diseases. The data from this independent comparative evaluation of
CryoStor is consistent with results of our internal research. Awareness of our enabling technology is
growing as clinical researchers and care givers realize how our proprietary products can enhance their
biologic-based therapies and services.”
According to an August 2006 research report published by Jain PharmaBiotech, the total value of cellbased
markets was $27 billion in 2005 and is expected to grow to $96 billion in 2015, as more than 300
companies are engaged in developing cell-based alternatives to medical devices and drugs to treat and
possibly cure numerous acute and chronic diseases. Additionally, PA Consulting Group, a global consulting
firm with expertise in life sciences and healthcare, estimates the worldwide market for media to preserve
cells, tissues, and organs for research and clinical applications will grow to from $200 million in 2007 to
more than $300 million by 2011.
This news release contains forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These forward-looking statements include any
statements that relate to the intent, belief, plans or expectations of the Company or its
management, or that are not a statement of historical fact. Any forward-looking statements in
this news release are based on current expectations and beliefs and are subject to numerous
risks and uncertainties that could cause actual results to differ materially. Some of the specific
factors that could cause BioLife Solutions' actual results to differ materially are discussed in the
Company's recent filings with the Securities and Exchange Commission. BioLife Solutions
disclaims any obligation to update any forward-looking statements as a result of developments
occurring after the date of this press release.